Sinusitis Treatment Drugs Market

Industry Outlook

The market for sinusitis treatment drugs had a market value of US$ 2,006.9 million in 2017 and is expected to grow at a CAGR of 3.2% between 2018 and 2026.Sinusitis is an inflammation of the paranasal sinuses caused by allergies, autoimmune reactions, or physical obstructions. According to the American Academy of Allergy, Asthma, and Immunology (AAAI), sinusitis is of two types: acute and chronic, where acute sinusitis symptoms last for less than four weeks, while chronic sinusitis is diagnosed when symptoms last for more than 12 weeks. Sinusitis affects approximately 40% of the population in the United States, resulting in an annual treatment expenditure of approximately US$ 8.6 billion. According to medical experts, acute sinusitis is usually of viral etiology, and patients are treated with supportive therapies such as nasal irrigation. In the case of chronic sinusitis, patients are on multiple regimens of antibiotics, local and systemic corticosteroid therapy, and other drugs. The key factors driving the global sinusitis drugs market are the high prevalence of sinusitis and its even higher incidence in the urban population. Shifts in lifestyle, growing urbanization and industrialization, and similar factors have led to increased air, water, and soil pollution worldwide. This, as a result, has led to increased exposure to infection-causing viruses and bacteria, thereby growing the risk of sinusitis. Furthermore, the evolution of sinusitis diagnosis from physical examination to novel endoscopy and computed tomography imaging techniques has resulted in an increased sinusitis diagnosis rate. This, in turn, has augmented the potential patient pool and thereby increased the demand for sinusitis treatments.

Market Synopsis

Decongestant and mucolytic agents are the first choices of drugs against non-microbial sinusitis, which is highly prevalent.

In 2017, decongestant and mucolytic agents accounted for the largest market share and were expected to maintain their dominance throughout the forecast period. The key factors responsible for market growth are the first line of action for non-infectious sinusitis, upcoming novel technologies of drug delivery, and increasing patient awareness, which has assisted the growth in disease diagnosis rates. During the forecast period from 2018 to 2016, antibiotics were observed as the fastest-growing segment due to key market drivers such as developing diagnostic technologies. As per the latest research quote published by the National Institute of Health (NIH), the incidence of acute sinusitis is 15 to 40 episodes per 1000 patients per year. Acute sinusitis is the second-most common infectious disease encountered by general practitioners throughout the globe.

With increasing awareness in the population about the severity of sinusitis and the rapid adoption of novel diagnostic techniques, Asia-Pacific is the fastest-growing region globally.

North America dominated the sinusitis treatment drug market due to key factors such as the rising prevalence of sinusitis coupled with developed diagnostic technologies and high disease awareness among patients and medical practitioners. In addition, upcoming novel drug delivery technologies are expected to assist the market’s growth in the near future. During the forecast period from 2018 to 2026, Asia-Pacific was observed as the fastest-growing region due to factors such as the rising prevalence of sinusitis, increasing awareness about nasal and sinus disorders in patients, and developing healthcare infrastructure with skilled healthcare professionals. In addition, swift urbanization and industrialization in key countries such as China, India, and Indonesia have led to air pollution in urban areas and increased the risk of sinusitis. China and India alone house the largest share of the global population, therefore presenting a significant patient pool.

Periods of History and Forecast

The sinusitis treatment market was analyzed considering current market trends for the base year of 2017, and based on future trends, CAGRs were calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report on the global market for sinusitis treatment offers in-depth information related to market dynamics and global trends. The report provides a comprehensive summary of the global sinusitis treatment market by segmenting the market based on treatment type and geography. The objective of publishing this in-depth research report is to assist industry stakeholders in carrying out decisions and strategy implementation in the sinusitis treatment market.

This report further describes the major qualitative assessment factors, including key market trends, market drivers, and market restraints, to assist in a better understanding of the global sinusitis treatment market. Furthermore, the key players were analyzed graphically based on their product offerings, market strategies, and business strengths. The report also provides an attractive investment proposition based on the extensive geographical research carried out based on PESTEL analysis. Key players profiled in the report include Pfizer, Inc., Janssen Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline Plc, Sanofi SA, Novartis AG, and Teva Pharmaceutical Industries, Ltd., among others.

Key questions are answered in this report.

• What are sinusitis treatments and their evolving applications?
• How the route of administration plays a key role in sinusitis treatment technology
• What are the recent market trends and growth opportunities for the companies operating in the sinusitis treatment industry?
• Which are the most attractive markets geographically for sinusitis treatment technology?
• Which is the fastest-growing application of sinusitis treatment?
• What is the competitive landscape of the sinusitis treatment drug market?

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.4 Assumptions

Chapter 2 Executive Summary
2.1 Global STD Market Portraiture
2.2 Global STD Market, by Treatment Type, 2017 (US$ Mn)
2.3 Global STD Market, by Geography, 2017 (US$ Mn)

Chapter 3 Global Sinusitis Treatment Drugs (STD) Market Analysis
3.1 Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 High Prevalence of Sinusitis
3.2.1.2 Rising Pollution Contributing to Increased Incidence of Sinusitis
3.2.2 Challenges
3.2.2.1 Overuse of Drugs and Excessive Self Medication
3.2.3 Market Opportunities
3.2.3.1 Big Opportunities for New Innovative Treatments
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Market Positioning: by Key Players in STD Market, 2016

Chapter 4 Global Sinusitis Treatment Drugs (STD) Market, by Treatment Type, 2018-2026 (US$ Mn)
4.1 Overview
4.2 Antibiotics
4.2.1 Cephalosporin Antibiotics
4.2.2 Penicillin/Beta Lactamase Inhibitors
4.2.3 Macrolide Antibiotics
4.2.4 Quinolone Antibiotics
4.3 NSAIDS
4.4 Decongestant & Mucolytic
4.4.1 Imidazoline Derivatives
4.4.2 Antihistamines
4.4.3 Corticosteroids
4.4.4 α₁-adrenergic receptor agonist
4.5 Nasal Irrigation Kits
4.6 Pipeline Analysis
4.6.1 Phase III
4.6.1.1 Omalizumab (F.Hoffman La-Roche AG)
4.6.2 Phase II and I (Tabular Format)

Chapter 5 Global Sinusitis Treatment Drugs (STD) Market, by Geography, 2016–2026 (US$ Mn)
5.1 Overview
5.2 North America
5.2.1 North America STD Market, by Treatment Type, 2016–2026 (US$ Mn)
5.2.2 North America STD Market, by Country, 2016–2026 (US$ Mn)
5.2.2.1 U.S.
5.2.2.2 Canada
5.3 Europe
5.3.1 Europe STD Market, by Treatment Type, 2016–2026 (US$ Mn)
5.3.2 Europe STD Market, by Region/Country, 2016–2026 (US$ Mn)
5.3.2.1 U.K.
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific
5.4.1 Asia Pacific STD Market, by Treatment Type, 2016–2026 (US$ Mn)
5.4.2 Asia Pacific STD Market, by Region/Country, 2016–2026 (US$ Mn)
5.4.2.1 Japan
5.4.2.2 China
5.4.2.3 Rest of Asia Pacific
5.5 Latin America (LATAM)
5.5.1 Latin America STD Market, by Treatment Type, 2016–2026 (US$ Mn)
5.5.2 Latin America STD Market, by Region/Country, 2016–2026 (US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of Latin America
5.6 Middle East & Africa (MEA)
5.6.1 Middle East & Africa STD Market, by Treatment Type, 2016–2026 (US$ Mn)
5.6.2 Middle East & Africa STD Market, by Region, 2016–2026 (US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of Middle East & Africa

Chapter 6 Company Profiles
6.1 Pfizer, Inc.
6.2 Abbott Laboratories, Inc.
6.3 Janssen Pharmaceuticals, Inc.
6.4 GlaxoSmithkline, Plc.
6.5 Sanofi SA
6.6 Sandoz International GmbH (a subsidiary of Novartis International AG)
6.7 Bayer AG
6.8 Merck & Co., Inc.
6.9 Sun Pharmaceutical Industries Ltd.
6.10 Teva Pharmaceutical Industries Ltd.

List of Figures

FIG. 1 Research Methodology: Global Sinusitis Treatment Drugs (STD) Market
FIG. 2 Global STD Market, by Treatment Type, 2017 (US$ Mn)
FIG. 3 Global STD Market, by Geography, 2017 (US$ Mn)
FIG. 4 Classification of Adult Rhinosinusitis
FIG. 5 Attractive Investment Proposition: Global STD Market, by Geography, 2017
FIG. 6 Market Positioning of Key Players in STD Market, 2017
FIG. 7 Global Cephalosporin Antibiotics Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 8 Global Penicillin/Beta Lactamase Inhibitors Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 9 Global Macrolide Antibiotics Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 10 Global Quinolone Antibiotics Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 11 Global NSAIDS Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 12 Global Imidazoline Derivatives Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 13 Global Antihistamines Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 14 Global Corticosteroids Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 15 Global A₁-adrenergic Receptor Agonist Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 16 Global Nasal Irrigation Kits Market for Sinusitis Treatment, 2016-2026 (US$ Mn)
FIG. 17 U.S. STD Market, 2016–2026 (US$ Mn)
FIG. 18 Canada STD Market, 2016–2026 (US$ Mn)
FIG. 19 U.K. STD Market, 2016–2026 (US$ Mn)
FIG. 20 Germany STD Market, 2016–2026 (US$ Mn)
FIG. 21 Rest of Europe STD Market, 2016–2026 (US$ Mn)
FIG. 22 Japan STD Market, 2016–2026 (US$ Mn)
FIG. 23 China STD Market, 2016–2026 (US$ Mn)
FIG. 24 Rest of Asia Pacific STD Market, 2016–2026 (US$ Mn)
FIG. 25 Brazil STD Market, 2016–2026 (US$ Mn)
FIG. 26 Mexico STD Market, 2016–2026 (US$ Mn)
FIG. 27 Rest of Latin America STD Market, 2016–2026 (US$ Mn)
FIG. 28 GCC STD Market, 2016–2026 (US$ Mn)
FIG. 29 Rest of Middle East & Africa STD Market, 2016–2026 (US$ Mn)

List of Tables

TABLE 1 Global Sinusitis Treatment Drugs (STD) Market Portraiture
TABLE 2 Global STD Market, by Treatment Type, 2016–2026 (US$ Mn)
TABLE 3 Global Antibiotics Market for Sinusitis Treatment, 2016–2026 (US$ Mn)
TABLE 4 Global Decongestant & Mucolytic Market for Sinusitis Treatment, 2016–2026 (US$ Mn)
TABLE 5 Global STD Market, by Geography, 2016–2026 (US$ Mn)
TABLE 6 North America STD Market, by Treatment Type, 2016–2026 (US$ Mn)
TABLE 7 North America STD Market, by Country, 2016–2026 (US$ Mn)
TABLE 8 Europe STD Market, by Treatment Type, 2016–2026 (US$ Mn)
TABLE 9 Europe STD Market, by Region/Country, 2016–2026 (US$ Mn)
TABLE 10 Asia Pacific STD Market, by Treatment Type, 2016–2026 (US$ Mn)
TABLE 11 Asia Pacific STD Market, by Region/Country, 2016–2026 (US$ Mn)
TABLE 12 Latin America STD Market, by Treatment Type, 2016–2026 (US$ Mn)
TABLE 13 Latin America STD Market, by Region/Country, 2016–2026 (US$ Mn)
TABLE 14 Middle East & Africa STD Market, by Treatment Type, 2016–2026 (US$ Mn)
TABLE 15 Middle East & Africa STD Market, by Region, 2016–2026 (US$ Mn)
TABLE 16 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Jansenn Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 GlaxoSmithkline, Plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Sanofi SA: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Sandoz International GmbH (a subsidiary of Novartis International AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
TABLE 23 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
TABLE 24 Sun Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)
TABLE 25 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; Key Developments)